Journal article

Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia

Natalie K Binder, Fiona C Brownfoot, Sally Beard, Ping Cannon, Tuong V Nguyen, Stephen Tong, Tu'uhevaha J Kaitu'u-Lino, Natalie J Hannan

PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH | ELSEVIER SCI LTD | Published : 2020

Abstract

Development and repurposing of therapies that show promise in the prevention or treatment of preeclampsia would be a major advance for the obstetrics field. We recently identified esomeprazole and sulfasalazine as potential candidates for the treatment of preeclampsia. Both reduce placental and endothelial secretion of sFlt-1 and sENG and mitigate endothelial dysfunction in vitro. Here we assessed whether esomeprazole and sulfasalazine in combination would additively attenuate the elevated release of anti-angiogenic factors and markers of endothelial dysfunction, key characteristics of preeclampsia. Primary placental tissue and cells, and primary endothelial cells were treated with esomepraz..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by NHMRC


Funding Acknowledgements

This study was funded by the Norman Beischer Medical Research Foundation and a grant from the National Health and Medical Research Council of Australia (NHMRC #1101871). The NHMRC also provided salary support (TKL; #1159261 FB; #1142636 ST; #1136418 and NJH; #1146128). The funders had no role in study design, data collection, analysis or decision to publish.